FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin For Approval For Cutaneous T-cell Lymphoma

Gloucester Pharmaceuticals announced that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.